BIOMARIN PHARMACEUTICAL INC (BMRN) is a publicly traded company in the Unknown sector. Across all available filings, 29 corporate insiders have executed 1004 transactions totaling $207.1M, demonstrating a bearish sentiment with -$204.5M in net insider flow. The most recent transaction on Dec 1, 2025 involved a transaction of 16,570 shares valued at $911.8K.
No significant insider buying has been recorded for BMRN in the recent period.
No significant insider selling has been recorded for BMRN in the recent period.
Based on recent SEC filings, insider sentiment for BMRN is bearish with an Insider Alignment Score of 1/100 and a net flow of -$204.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at BIOMARIN PHARMACEUTICAL INC (BMRN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 29 insiders are actively trading BMRN stock, having executed 1004 transactions in the past 90 days. The most active insider is Jean Jacques Bienaime (Executive), who has made 362 transactions totaling $186.5M.
Get notified when executives and directors at BMRN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | Hardy Alexander | Executive | Payment | 16,570 | $55.03 | $911.8K | Large |
| Sep 30, 2025 | R. Friberg Gregory | Executive | Payment | 3,304 | $54.16 | $178.9K | |
| Aug 1, 2025 | T. Clark Ian | Executive | Award | 7,000 | $N/A | $0 | |
| Apr 30, 2025 | Hardy Alexander | Executive | Award | 375 | $54.14 | $20.3K | |
| Sep 13, 2024 | J. Fuchs Henry | Executive | Payment | 12,098 | $84.90 | $1.0M | Large |
| Aug 13, 2024 | Burkhart Erin | Executive | Sale | 714 | $90.00 | $64.3K | 10b5-1 |
| Jun 3, 2024 | A. Meier Richard | Executive | Option Exercise | 6,600 | $63.10 | $416.5K | |
| Jun 3, 2024 | A. Meier Richard | Executive | Payment | 5,451 | $76.41 | $416.5K | |
| Jun 3, 2024 | J. Heron Elaine | Executive | Option Exercise | 5,047 | $63.10 | $318.5K | |
| Jun 3, 2024 | J. Heron Elaine | Executive | Payment | 4,168 | $76.41 | $318.5K | |
| May 30, 2024 | Mueller Brian | Executive | Option Exercise | 5,000 | $63.10 | $315.5K | 10b5-1 |
| May 30, 2024 | Mueller Brian | Executive | Sale | 5,000 | $75.19 | $375.9K | 10b5-1 |
| May 28, 2024 | Eric Davis George | Executive | Sale | 38,071 | $74.46 | $2.8M | Large10b5-1 |
| May 28, 2024 | Eric Davis George | Executive | Sale | 2,779 | $75.29 | $209.2K | 10b5-1 |
| May 28, 2024 | Eric Davis George | Executive | Option Exercise | 40,850 | $63.10 | $2.6M | Large10b5-1 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 324 | $205.8M | 53.9% |
Payment(F) | 153 | $90.2M | 23.6% |
Exercise(M) | 231 | $83.7M | 21.9% |
Purchase(P) | 3 | $1.3M | 0.3% |
Award(A) | 257 | $989.2K | 0.3% |
Small Acquisition(L) | 9 | $42.4K | 0.0% |
Gift(G) | 27 | $0 | 0.0% |
Insider selling pressure at BIOMARIN PHARMACEUTICAL INC has increased, with 29 insiders executing 1004 transactions across all time. Total sales of $205.8M significantly outpace purchases of $1.3M, resulting in a net outflow of $204.5M. However, 44% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.